Mesoblast Limited American Depositary Shares
MESOStock
$17.86+19.91%52W
Market Cap$3.36B
P/E—
Div yield—
Beta1.86
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-12.27%
Price vs S&P 500 (4W)29.45%
VGM Score56.76
Market Capitalization$3.36B
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.10
4.10
4.10
4.10
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MESOMesoblast Limited American Depositary Shares | D | B | B | $17.86 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Mesoblast is a commercial-stage biotechnology company developing allogeneic cellular medicines for serious inflammatory and degenerative diseases. Key programs include Ryoncil for steroid-refractory acute graft-versus-host disease and acute respiratory distress syndrome, Revascor for chronic heart failure, and a candidate for chronic low back pain. The company leverages a proprietary adult stem cell technology platform designed for off-the-shelf therapeutic applications.